Life Sciences Collaborations and the Risk of Joint Patent Infringement

Why It Matters

This delineation shapes how multinational life‑science consortia structure R&D and supply agreements, influencing litigation exposure and commercial strategy in the Canadian market.

Key Takeaways

• Canada exempts experimental and regulatory‑submission activities from patent infringement
• Joint liability arises for collaborators sharing a common infringing design
• Supplying a single patent element abroad does not constitute infringement in Canada
• Videotron case shows liability hinges on contract ties, not just component supply
• Appeal court confirms development work is safe if it stops before making

Pulse Analysis

Canada’s patent framework offers life‑science companies a rare degree of protection, especially for activities tied to regulatory filings or experimental research. Sections 55.2(1) and 55.3(1) of the Patent Act carve out exemptions that let firms develop, test, and compile data for foreign approvals without fearing infringement claims. This regulatory safe harbor is crucial for global drug developers that must generate extensive data sets before a product ever reaches the Canadian market, allowing them to focus resources on innovation rather than defensive litigation.

The Federal Court’s 2025 ruling in Adeia Guides Inc v. Videotron Ltd added nuance to the exemption landscape. While the decision did not hinge on the doctrine of common‑design infringement, it affirmed that a Canadian entity can be held jointly liable when a contractual relationship creates a shared intent to infringe. The court’s focus on the Videotron‑Comcast agreement, rather than the technical contributions of each party, signals that the existence and scope of contracts may be the decisive factor in joint liability assessments. Foreign suppliers, however, remain insulated unless they are part of a coordinated plan that directly leads to the sale of an infringing product in Canada.

Practically, life‑science firms should audit collaboration agreements for clauses that could be interpreted as a common design to infringe. Clear delineation of responsibilities, especially where one partner only provides a component or data, helps preserve the statutory immunity. Companies are also advised to document the separation between development activities and commercial exploitation, ensuring that any testing stops short of making or using the patented invention. As Canadian courts continue to refine the boundaries of joint liability, proactive contract management and compliance monitoring will be essential to mitigate risk while leveraging the country’s generous patent exemptions.